Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Jan;12(1):113-6.
doi: 10.1023/a:1016251023427.

Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis

Affiliations

Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis

M A Jaser et al. Pharm Res. 1995 Jan.

Abstract

The pharmacokinetics of Sb was examined in 29 patients with cutaneous leishmaniasis following the intramuscular administration of a dose of sodium stibogluconate equivalent to 600 mg of Sb. Blood was sampled at different time intervals from each patient and Sb was measured in whole blood by electrothermal atomic absorption spectrophotometry after an appropriate dilution with Triton X-100. The 24-hr urine was also collected and analyzed similarly. The blood concentration-time data conformed to the one-compartment open model with mean and (SEM) of the apparent first-order rate constants for absorption (ka) and elimination (kd) of 1.71 (0.15) and 0.391 (0.016) hr-1, respectively. The maximum concentration of Sb achieved was 8.77 (0.39) mg/L and the peak time was 1.34 (0.09) hr. The total body clearance (TBC) and the volume of distribution (Vd) were 17.67 (1.38) L/hr and 45.7 (2.6) L, respectively, assuming a complete absorption. The fraction of dose of Sb excreted in the urine was 0.80 (0.07) and the renal clearance was 12.7 (1.16) L/hr. The frequency distribution pattern of the area-under-the-curve (AUC) appears to be bimodal and separates patients into those with low exposure to Sb (AUC = 11.7-29.04 mg.hr/L) (i.e., rapid eliminators) and those with high exposure to Sb (AUC = 31.5-49.1 mg.hr/L) (i.e., slow eliminators). This may explain the variability observed in the response to treatment of leishmaniasis with sodium stibogluconate.

PubMed Disclaimer

References

    1. Clin Chim Acta. 1989 Feb 22;179(3):341-5 - PubMed
    1. Trans R Soc Trop Med Hyg. 1988;82(1):69-72 - PubMed
    1. J Trop Med Hyg. 1949 Oct;52(10):199-204 - PubMed
    1. Trans R Soc Trop Med Hyg. 1986;80(4):670-1 - PubMed
    1. Trans R Soc Trop Med Hyg. 1982;76(4):531-7 - PubMed

Publication types

LinkOut - more resources